Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
CytoMed Therapeutics Limited - Ordinary Shares
(NQ:
GDTC
)
2.040
+0.030 (+1.49%)
Streaming Delayed Price
Updated: 2:19 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CytoMed Therapeutics Limited - Ordinary Shares
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
October 07, 2024
Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
October 03, 2024
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
September 30, 2024
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
July 17, 2024
Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration
March 20, 2024
The global population is rapidly aging. According to the World Population Prospects 2022 published by the United Nations, there were
Via
Spotlight Growth
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
March 20, 2024
Via
ACCESSWIRE
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
March 18, 2024
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
March 04, 2024
CytoMed diversifies into regenerative medicine
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
January 29, 2024
The Company now has exclusive rights to a Malaysia, US and China patent
From
CYTOMED THERAPEUTICS LIMITED
Via
GlobeNewswire
Singapore’s Journey to Becoming a Biotech Powerhouse
October 24, 2023
Singapore's Biotech Vision: From 2000 Onwards In 2000, Singapore embarked on an ambitious mission to establish itself as a leading
Via
Spotlight Growth
Topics
Economy
Exposures
Economy
CytoMed Expands Research Collaboration into China After Entering Into MOU
August 29, 2023
Via
ACCESSWIRE
Singapore’s Leap into the Future of Cell and Gene Therapies
August 29, 2023
Singapore is making remarkable progress in the realm of cell and gene therapy (CGT), as evidenced by the inauguration of
Via
Spotlight Growth
The Dawn of a New Era in Immunotherapy for Cancers: Understanding CytoMed Therapeutics’ (NASDAQ: GDTC) iPSC-Derived Gamma Delta NKT Cell Technology
July 27, 2023
CytoMed Therapeutics, a NASDAQ-listed company (Stock Symbol: GDTC), is at the forefront of a revolution in cellular therapy for cancers.
Via
Spotlight Growth
CytoMed Therapeutics Collaborates With Cancer Treatment Center to Advance Its Unique CAR-T Technology
June 28, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
CytoMed (NASDAQ: GDTC): Revolutionizing Cancer Treatment with Unique CAR-T Cell Technology
June 28, 2023
Despite the substantial advances in medical technology, cancer remains a formidable foe with an alarming annual growth rate. According to
Via
Spotlight Growth
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.